2021-2022 University of Chicago Inflammatory Bowel Disease Preceptorship
Please note: the CME accredited portion of this program is part of the 2021-2022 IBD Preceptorship Program, which consists of three phases. The self-study component of this program can only be completed as part of the full program.
The 2021-2022 IBD Preceptorship Program consists of:
- One month self-study (CME-accredited)
- One month virtual preceptorship consisting of Zoom meeting attendance at the University of Chicago Medicine IBD Center’s research in progress meetings, multidisciplinary conferences, and case discussion roundtables, and mentoring meetings with faculty. Note: some of these activities are also certified for CME credit.
- Two day on site, in person clinical observership at the University of Chicago Medicine IBD Center, after COVID-related visitor restrictions have lifted, consisting of clinic observations, inpatient rounding, and/or procedures with IBD faculty. All related travel expenses, meals, and lodging will be reimbursed.
Series of journal articles with self-reflection questions
Reading, Self-Reflection, and Evaluation: 8 hour and 15 minutes
At the conclusion of this activity, participants will be able to:
- Recall the latest developments in IBD research;
- Describe key concepts, evidence-based practice, and diagnosis techniques found in IBD research;
- Evaluate treatment options for complicated patient cases in both clinical and hospital settings;
- Explain the latest advances in diagnostic and therapeutic options for IBD;
- Identify gaps in practice in the treatment of patients with IBD;
- Discuss steps to close those practice gaps.
UNIVERSITY OF CHICAGO COURSE LEADERSHIP
Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
Sushila Dalal, MD
Assistant Profressor of Medicine
Joel Pekow, MD
Associate Professor of Medicine
David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
Atsushi Sakuraba, MD, PhD
Associate Professor of Medicine
Administrative Director, University of Chicago Medicine IBD Center
Selected Publications & Additional Resources
Additional references for further study can be found in the journal articles.
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Russell D. Cohen, MD has served as a consultant and advisor for Abbvie Laboratories, BMS/ Celgene, Eli Lilly, Genentech, Gilead Sciences, Hoffmann La-Roche, Janssen, Pfizer, Takeda, and UCB Pharma. Dr. Cohen has received grant funding from Abbvie, BMS/Celgene, Boehringer Ingelheim, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd., Osiris Therpeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, and UCB Pharma.
Sushila Dalal, MD has served on the speaker’s bureau for AbbVie and as a consultant for Pfizer.
Joel Pekow, MD has served on the advisory board of Takeda and as a consultant for Genetech and Verastem.
David T. Rubin, MD has served as a consultant for Abbvie, Altrubio, Allergan, Inc., Arena Pharmaceuticals, Athos Therapeutics, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Pfizer, Prometheus Biosciences, Reistone, and Takeda.
Atsushi Sakuraba, MD, PhD, Anna Gomberg, and the staff of the Center for Continuing Medical Education have no relevant financial relationships with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
INSTRUCTIONS FOR PARTICIPATION AND CLAIMING CREDIT
Physicians are eligible to receive continuing education credit applicable to their profession. All other participants will receive a certificate indicating participation in this AMA PRA Category 1 Credit™-approved activity. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
The information presented in this activity is for continuing medical education purposes only. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the University of Chicago Pritzker School of Medicine, the University of Chicago Medicine, or the Department/Section.